Background. A body-weight-based dose of tacrolimus often results in marked individual
diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450 (CYP) …

We retrospectively examined the association of polymorphisms in the CYP3A, CYP2J2,
CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) …

Purpose The purpose of this study was to characterize the effects of clinical and genetic
variables on the pharmacokinetics and complications of tacrolimus during the first year after …

Aims: This prospective study investigated the effect of genetic polymorphisms in a
biotransformation enzyme (CYP3A5) and a transporter protein (ABCB1) on tacrolimus (Tac) …

Purpose: We aimed to investigate the association between ATP Binding Cassette Subfamily
B Member 1 (ABCB1) single nucleotide polymorphisms (SNPs) and the pharmacokinetics of …

Tacrolimus (TAC) is an immunosuppressant drug that prevents organ rejection after
transplantation. This drug is transported from cells via P-glycoprotein (ABCB1) and is a …

Background Polymorphisms in genes encoding transport proteins and metabolizing
enzymes involved in tacrolimus (TAC) disposition may be important sources of individual …

OBJECTIVES: To study the prevalence and clinical significance of polymorphisms in the
CYP3A5 and MDR1 genes in liver transplant patients and their donors; to determine the …

Abstract Background and Objective Tacrolimus is an immunosuppressive drug used for the
prevention of the allograft rejection in kidney transplant recipients. It exhibits a narrow …

Tacrolimus (TAC) is the backbone of an immunosuppressive drug used in most solid organ
transplant recipients. A single nucleotide polymorphism (SNP) at position 6986G> A in …